source
- Braveheart Bio targets $382 million IPO to fund cardiac drug developmentBraveheart Bio announced an upsized initial public offering on the Nasdaq, aiming to raise about $382.5 million. The company will sell 21.2 million shares at $18 each under the ticker BRVE. The pr…
- AI’s role in medicine isn’t monolithic, says industry leader, urging nuanced adoptionPriya Abani, CEO of health‑tech firm AliveCor, argues that asking whether AI is good for medicine is a question with an obvious answer: it is. She says the debate has become redundant and that the…